On a DART-filed basis, revenue rose from KRW 1.29 billion in 2022 to KRW 3.12 billion in 2023 (up 142.5% year on year), fell to KRW 2.5 billion in 2024 (down 19.9%), and reached KRW 3.69 billion in 2025 (up 47.7%), the largest year in the 2022 to 2025 period.
The operating loss was KRW 20 billion in 2022, KRW 22.4 billion in 2023, KRW 16.1 billion in 2024 and KRW 15.6 billion in 2025, a four-year run of losses from 2022 through 2025. The loss peaked in 2023 and narrowed in 2024 and 2025, and the operating margin moved from -1,556.7% in 2022 to -421.8% in 2025.
Revenue grew faster than losses shrank in relative terms, but revenue is still far below the operating loss, so the path to a healthier income structure remains open.
Net loss attributable to controlling shareholders was KRW 19.2 billion in 2022, KRW 21.6 billion in 2023, KRW 20.2 billion in 2024 and KRW 19.5 billion in 2025, and the net loss including non-controlling interests followed the same pattern.
The debt-to-equity ratio jumped to 310.8% in 2024, a period when reports said total equity was about KRW 6.5 billion at year-end 2024.
The perpetual convertible bonds were fully recognized as equity, lifting total equity to KRW 40 billion at end-2025, with total liabilities of KRW 12.7 billion and a debt ratio of 31.7%.
Operating cash flow was negative in every year, at -KRW 16.6 billion in 2022, -KRW 20.7 billion in 2023, -KRW 12.9 billion in 2024 and -KRW 15.1 billion in 2025.
Quarterly revenue went from KRW 980 million in the third quarter of 2025 to KRW 794 million, KRW 726 million and KRW 646 million, then KRW 666 million in the third quarter of 2026, which was down 32.0% from a year earlier.
Operating losses over the same five quarters were KRW 3.72 billion, KRW 4.6 billion, KRW 4.04 billion, KRW 4.22 billion and KRW 3.88 billion, and the net loss attributable to controlling shareholders over the last four quarters totaled KRW 18.3 billion.
R&D spending in the first half of 2026 was KRW 2.8 billion, equal to 135.6% of revenue, so development costs continue to exceed sales.